The CTA phase one study has not started yet due to some minor.......
Shorts have been furiously posting trying to take advantage of that
Your analysis ignores the shares that have been naked shorted.
Have you looked at the fail to deliver data lately?
You need to look below the surface to see the real story
Good question and nice analysis.
Now that the dosing trial is about to FINALLY get started in Europe, it appears Dr Mullan is finally ready to start ramping up the visibility of this company via presentations etc.. That will be key to kicking off a robust M&A environment.
Despite the efforts of the shorts, I believe a M&A bidding war is possible.
As Dr Mullan said at the shareholders meeting, RCPI is unique from other pharma startups at this stage due to the large amount of data already collected. Looks to me like Dr Mullan is now ready to start leveraging that data to secure RCPI's future.
I also like that this upcoming presentation will be webcast. That opens the door for major announcements within the SEC disclosure rules.
It will be interesting see what new information Dr Mullan is ready to make public.
Why is this presentation being webcast?
Is it to comply with SEC disclosure SEC rules?
Will something new be disclosed?
Funny how you shorts are sure a reverse split is coming.
I am waiting to see what news comes before the Nasdaq deadline is reached.
Now we start to see all the rationalization posts from the shorts.
Where are the shorts going to get shares if good news starts coming out?
Shorts have been unable to cover any significant amount since the Russell rebalancing.
Dedicated longs are not selling and there is very little institutional ownership.
Shorts were hoping that delisting would eliminate the need to cover.
Anybody who listened to the shareholders meeting knows that Dr Mullan has a plan and he obviously convinced Nasdaq the extension was appropriate.
The shorts can cry all they want but those are the facts!